An Open-label, Phase II Study Evaluating the Safety and Efficacy of the Addition of Capecitabine (Xeloda®) to Radiation Therapy Compared to Historical Control, in Children With Newly-diagnosed Non-disseminated Intrinsic Diffuse Brain Stem Gliomas.

Inclusion Criteria:

- pediatric and adolescent patients >/=3 to <18 years of age

- patients must have a newly diagnosed non-disseminated intrinsic infiltrating
brainstem glioma

- Karnofsky Performance Scale (if >16 years of age) or Lansky Performance Score (if
/= 50% assessed within two weeks prior to registration to study

- patients must not have received any prior chemotherapy or bone marrow transplant for
the treatment of brainstem glioma. Prior dexamethasone and/or surgery are allowed.

- adequate organ function

Exclusion Criteria:

- patients receiving any other anticancer or experimental drug therapy

- patients with uncontrolled infection

- known DPD deficiency